3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Lymphoid
1
Head & Neck
1
Gastrointestinal
1
Breast
1
Conditions
Melanoma
98
Carcinoma, Non-Small-Cell Lung
32
Neoplasms
22
Neoplasm Metastasis
14
Carcinoma, Renal Cell
13
Prostatic Neoplasms
12
Lung Neoplasms
12
Small Cell Lung Carcinoma
10
Diabetes Mellitus, Insulin-Dependent, 12
10
Pancreatic Neoplasms
7
Uveal Melanoma
6
Skin Neoplasms
6
Ovarian Neoplasms
6
Brain Neoplasms
6
Advanced Cancer
6
Squamous Cell Carcinoma of Head and Neck
5
Sarcoma
5
Mesothelioma
5
Multiple Myeloma
4
Lymphoma, Non-Hodgkin
4
Lymphoma
4
Kidney Neoplasms
4
Hodgkin Disease
4
Head and Neck Neoplasms
4
Carcinoma, Transitional Cell
4
Carcinoma, Merkel Cell
4
Carcinoma, Hepatocellular
4
Carcinoma
4
Breast Neoplasms
4
Various Advanced Cancer
3
Interventions
Cisplatin
27
Cetuximab
17
Radiotherapy
14
Carboplatin
14
pembrolizumab
11
Paclitaxel
11
Drug Therapy
8
Radiotherapy, Intensity-Modulated
7
Nivolumab
7
Fluorouracil
7
Erlotinib Hydrochloride
7
Radiation
6
Docetaxel
5
130-nm albumin-bound paclitaxel
5
Panitumumab
4
Chemoradiotherapy
3
Capecitabine
3
Bevacizumab
3
Albumin-Bound Paclitaxel
3
Afatinib
3
selinexor
2
figitumumab
2
Restraint, Physical
2
Radiosurgery
2
Methotrexate
2
Lapatinib
2
Everolimus
2
Esophagectomy
2
Cyclophosphamide
2
zalutumumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Carcinoma, Squamous Cell
×
Ipilimumab
×
Clear all
NCT03058289
2025-02-27
IT-01
Intensity Therapeutics, Inc.
Phase 1/2
Completed
111 enrolled
21 charts